Literature DB >> 2990641

Different actions of vitamin D2 and D3 on bone metabolism in patients treated with phenobarbitone/phenytoin.

L Tjellesen, A Gotfredsen, C Christiansen.   

Abstract

In 22 epileptic outpatients treated for at least 1 year with phenobarbitone/phenytoin the local and total bone mass, together with serum and urinary indices of calcium metabolism, were measured before and during treatment with either vitamin D2 or D3, 4,000 IU daily for 24 weeks. The results showed a distinct difference in the action of the two vitamins on bone metabolism during anti-convulsant treatment. The bone mass increased during treatment with vitamin D2, whereas the vitamin D3-treated patients showed unchanged values of bone mass, but an increased excretion rate of calcium, probably caused by increased intestinal calcium absorption. The data demonstrate that vitamins D2 and D3 (or their metabolites) have quantitative different effects in patients treated with phenobarbitone/phenytoin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990641     DOI: 10.1007/bf02554866

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  18 in total

1.  Actions of vitamins D2 and D3 and 25-OHD3 in anticonvulsant osteomalacia.

Authors:  C Christiansen; P Rodbro; O Munck
Journal:  Br Med J       Date:  1975-05-17

2.  Recommended methods for the determination of four enzymes in blood.

Authors: 
Journal:  Scand J Clin Lab Invest       Date:  1974-06       Impact factor: 1.713

3.  Bone density in patients receiving long-term anticonvulsant therapy.

Authors:  J Linde; J Molholm Hansen; K Siersbaek-Nielsen; V Fuglsang-Fredriksen
Journal:  Acta Neurol Scand       Date:  1971       Impact factor: 3.209

4.  Total body bone mineral in vivo by dual photon absorptiometry. II. Accuracy.

Authors:  A Gotfredsen; J Borg; C Christiansen; R B Mazess
Journal:  Clin Physiol       Date:  1984-08

Review 5.  Vitamin D metabolism and its clinical application.

Authors:  J A Kanis
Journal:  J Bone Joint Surg Br       Date:  1982

6.  An easy and reliable method for determination of urinary hydroxyproline.

Authors:  J Pødenphant; N E Larsen; C Christiansen
Journal:  Clin Chim Acta       Date:  1984-09-15       Impact factor: 3.786

7.  Anticonvulsant drug-induced osteomalacia: alterations in mineral metabolism and response to vitamin D3 administration.

Authors:  T J Hahn; L R Halstead
Journal:  Calcif Tissue Int       Date:  1979-03-13       Impact factor: 4.333

8.  Osteomalacia with long-term anticonvulsant therapy in epilepsy.

Authors:  C E Dent; A Richens; D J Rowe; T C Stamp
Journal:  Br Med J       Date:  1970-10-10

9.  Long-term reproducibility of bone mineral content measurements.

Authors:  C Christiansen; P Rödbro
Journal:  Scand J Clin Lab Invest       Date:  1977-06       Impact factor: 1.713

10.  Bone mineral content before and after intestinal bypass operation in obese patients.

Authors:  H Rickers; I Balslev; H Foltved; P Rødbro
Journal:  Acta Med Scand       Date:  1981
View more
  4 in total

Review 1.  Cytochrome P450-mediated metabolism of vitamin D.

Authors:  Glenville Jones; David E Prosser; Martin Kaufmann
Journal:  J Lipid Res       Date:  2013-04-06       Impact factor: 5.922

2.  Maternal compared with infant vitamin D supplementation.

Authors:  M Ala-Houhala; T Koskinen; A Terho; T Koivula; J Visakorpi
Journal:  Arch Dis Child       Date:  1986-12       Impact factor: 3.791

3.  Irreversible bone loss in osteomalacia. Comparison of radial photon absorptiometry with iliac bone histomorphometry during treatment.

Authors:  A M Parfitt; D S Rao; J Stanciu; A R Villanueva; M Kleerekoper; B Frame
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

4.  Association of vitamin D2 and D3 with type 2 diabetes complications.

Authors:  Lina H M Ahmed; Alexandra E Butler; Soha R Dargham; Aishah Latif; Amal Robay; Omar M Chidiac; Amin Jayyousi; Jassim Al Suwaidi; Ronald G Crystal; Stephen L Atkin; Charbel Abi Khalil
Journal:  BMC Endocr Disord       Date:  2020-05-15       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.